Journal
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Volume 104, Issue 5, Pages 374-378Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1742-7843.2008.00370.x
Keywords
-
Categories
Funding
- FONDECYT [1010992]
- FONDAP [15010006]
- DID [14-02/01]
Ask authors/readers for more resources
We investigated the clinical response of chronic heart failure patients with beta(2)- adrenergic receptor Gln(27)-> Glu polymorphism treated for 6 months with carvedilol, a alpha/beta-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln(27)-> Glu beta(2)-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu(27)->beta(2)-adrenergic receptor allele. There were however, no significant changes in patients with the Gln(27)->beta(2)-adrenergic receptor variant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available